Project Grant R01HL176819
Award Date
12/5/24
Completion Date
11/30/28
Dollars Obligated
$735K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $165,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Dana-Farber Cancer Institute, Inc. (DFCI) to research the association between clonal hematopoiesis (CH) and inflammatory disease outcomes. The goal is to define the relationship between CH and rheumatologic diseases, identify CH genotypes linked to inflammatory phenotypes, and explore the influence of hypomethylating agent therapy on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to define the mechanisms that control the bone marrow niche and its impact on clonal hematopoiesis, a condition that increases the risk of life-threatening diseases. The $802,301 award, with a period of performance from June 2025 to April 2029, will support research conducted by Weill Medical College of Cornell University to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to advance the understanding of hematopoietic stem cell (HSC) regulation in low oxygen (hypoxic) conditions. The central goal is to examine how hypoxia alters gene expression and metabolic processes in HSCs to support self-renewal and prevent oxidative damage or differentiation. The 4-year, $792,498 award to the Trustees of Indiana...
This $1,276,687 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to improve understanding of the factors driving clonal hematopoiesis (CH) evolution and its association with age-related diseases like cardiovascular disease and Alzheimer's disease. The primary awardee, The Washington University, will leverage data from large biobanks and unique cohorts to: (1) determine the impact of lifestyle and inherited risk factors on CH evolution, (2) identify the...
This $493,810 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research focused on understanding how hematopoietic stem and progenitor cells (HSPCs) interact with their surrounding microenvironment, or "niche", during different stages of development. The research utilizes zebrafish and mouse models to investigate two specific aims: 1) Determine the role of vascular endothelial growth factor C (VEGFC) in...
This Project Grant award of $299,781 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to develop a first-in-class therapeutic regimen to attenuate aging of human hematopoietic stem cells (HSCs). The central goal is to demonstrate that targeting the CDC42 signaling pathway with the drug CASIN can restore polarity and rejuvenate aged human HSCs ex vvivo. This has the potential to benefit bone marrow HSC transplant...
This federal Project Grant award of $1,698,066.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a comprehensive research project to investigate the regulation of hematopoietic stem cell aging by the sympathetic nervous system. The principal objectives are to define the mechanisms of neural signal transduction in the bone marrow stem cell niche and examine how sympathetic nervous system-enabled stromal cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to investigate the mechanisms driving hematopoietic stem and progenitor cell (HSPC) dysfunction as a contributor to myeloid malignancies like myelodysplastic syndrome (MDS). The $146,922 award to the Albert Einstein College of Medicine will test the hypothesis that environmental alterations synergize with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
This $502,516 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the impacts of newly developed small molecule nuclear heat shock transcription factor 1 (HSF1) degraders on acute myeloid leukemia (AML) stem cell self-renewal. The grant recipient, Case Western Reserve University, will explore the underlying mechanisms of action of these HSF1 degraders in AML leukemic stem cells (LSCs) and identify associated biomarkers to...